OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
8
Results
Show all
Save search
Copy query
Show results for
Unknown
(8)
Publication Date
Release Date
2021
(2)
2024
(1)
2023
(1)
2019
(1)
2018
(1)
2013
(1)
2010
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.
Not available
S-EPMC3532391
|
biostudies-literature
Cite
First identification of Microsporidia MB in Anopheles coluzzii from Zinder City, Niger.
Not available
S-EPMC10826271
|
biostudies-literature
Cite
Transmission Routes of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae in a Neonatology Ward in Madagascar.
Not available
S-EPMC6553893
|
biostudies-literature
Cite
Estimation of French cattle herd immunity against bluetongue serotype 8 at the time of its re-emergence in 2015.
Not available
S-EPMC5834897
|
biostudies-literature
Cite
Effectiveness of two procedures for deploying a facilitated collaborative modeling implementation strategy-the PVS-PREDIAPS strategy-to optimize type 2 diabetes prevention in primary care: the PREDIAPS cluster randomized hybrid type II implementation trial.
Not available
S-EPMC8161614
|
biostudies-literature
Cite
Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis.
Not available
S-EPMC2840338
|
biostudies-literature
Cite
Fidelity evaluation of the compared procedures for conducting the PVS-PREDIAPS implementation strategy to optimize diabetes prevention in primary care.
Not available
S-EPMC7879624
|
biostudies-literature
Cite
A consensus protocol for functional connectivity analysis in the rat brain.
Not available
S-EPMC10493189
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets